Vardenafil can cause adverse reactions even when correctly prescribed and dispensed. Common reactions in U.S. film-coated tablet studies include headache, flushing, nasal symptoms and indigestion; dizziness and nausea were also reported. Not everyone develops these symptoms, and trial rates should not be treated as a prediction for an individual patient.
Some potential harms deserve a different response from routine bothersome symptoms. A prolonged erection, sudden vision or hearing loss, severe allergic symptoms, syncope, or concerning chest symptoms require urgent medical attention. Vardenafil also has a specific QT-prolongation precaution and contraindications with nitrates and riociguat, which may matter before treatment is prescribed.
This page focuses on adverse reactions and symptom triage rather than cataloguing every possible medicine combination. The interaction review is on the drug-interactions page, and the separate nitrate page explains one especially dangerous contraindication.
Placebo-controlled film-coated tablet trials reported headache, flushing, rhinitis and dyspepsia more often with vardenafil than placebo. Other recorded complaints included nausea, dizziness and certain sinus symptoms. A reported event in a trial is not automatically caused by medication in every individual case.
Trial populations and durations differ, so these figures cannot be compared directly to rates for another ED drug or used to rank agents by overall tolerability. The table groups representative reactions by their main practical relevance rather than presenting a patient-specific probability.
| Reaction | Typical reported experience | What to discuss |
|---|---|---|
| Headache | Head pain after dosing | Severity, recurrence and other symptoms |
| Flushing | Warmth or redness | Whether accompanied by faintness |
| Rhinitis/congestion | Runny or congested nose | Persistence and breathing concerns |
| Dyspepsia/nausea | Upper-abdominal discomfort | Severity, hydration and recurrence |
| Dizziness | Lightheadedness | Blood pressure, falls and co-medications |
Vardenafil influences the nitric-oxide/cGMP pathway involved in blood-vessel relaxation. Headache and flushing are compatible with vasodilator effects and are among commonly reported adverse reactions. They can be uncomfortable even in the absence of a serious complication.
Persistent, unusually severe or changing symptoms should be reviewed with a clinician. Do not infer that a strong headache means the medicine is working especially well or that adverse effects justify using additional tablets.
Nasal symptoms and upper-gastrointestinal discomfort appear in product labeling and trials. Their presence alone does not identify a severe reaction, but intensity, persistence and accompanying symptoms affect the appropriate response.
A clinician may review the timing, other medication effects, relevant medical conditions, and whether continuing treatment is reasonable. A person should avoid improvising unrelated medicines without checking for interactions.
Postmarketing reports for PDE5 inhibitors include serious visual events such as non-arteritic anterior ischemic optic neuropathy and sudden hearing decrease or loss. A temporal association in reports does not automatically establish causation in each case, but the symptoms require prompt action.
If sudden loss of vision or hearing occurs, stop using the medicine and seek urgent medical evaluation. A history of relevant eye or hearing problems should be discussed before treatment.
Priapism means an erection that persists abnormally. The patient should obtain immediate medical care for an erection lasting more than four hours, even if it is not painful. Delaying treatment can damage erectile tissue and cause lasting loss of function.
This is not an exaggerated form of the medication’s intended benefit. It must be distinguished from a normal period during which a person may respond to stimulation; perceived drug duration does not justify waiting through a prolonged erection.
Vardenafil can lower blood pressure and has label warnings concerning congenital QT prolongation and use with certain class IA or class III antiarrhythmic medicines. Cardiovascular conditions may also make sexual activity itself inadvisable in some patients. This is why assessment precedes prescribing.
Fainting, serious chest discomfort or a severe allergic reaction should be assessed urgently. Recent vardenafil use must be communicated to emergency clinicians; nitrates are contraindicated, and a patient should not attempt self-treatment with nitroglycerin after use.
A headache after a correctly prescribed dose may be an adverse effect. Hypotension after combining a PDE5 inhibitor with a nitrate is a contraindicated interaction. Distinguishing those scenarios matters because preventive action and urgency differ significantly.
Other interactions, including CYP3A4 inhibitors and alpha-blockers, can raise exposure or enhance blood-pressure effects. See drug interactions for the broader medication review.
For a nonemergency symptom, note the exact generic or branded formulation, strength, when it was taken, what occurred, how long the symptom lasted, and concurrent medicines. A clinician or pharmacist can consider the report in context and explain whether the plan needs reassessment.
Do not independently change dose, combine PDE5 agents, or rely on online reassurance for alarming symptoms. Patients and clinicians may also submit suspected adverse-event reports to FDA MedWatch through the appropriate channels.
Both formulations contain vardenafil and share important ingredient-level concerns, but their dosing instructions and systemic exposure are not identical. It is therefore unsafe to assume the same dosing or substitution rules merely because each may be marketed with a 10 mg label.
Confirm the dispensed form and all current directions. The ODT guide covers formulation issues and the dosage page explains why medical circumstances affect prescribing.
In the label’s placebo-controlled trials of film-coated vardenafil, headache, flushing and rhinitis were reported more frequently among treated participants than among placebo recipients. The proportions reflect people enrolled under particular study rules, not a certainty that those symptoms will occur for a patient filling a prescription today.
Clinical trial reports may also group events or use different observation periods. Rates from two separate drug labels should not be placed side by side as though they came from a randomized head-to-head comparison.
Ordinary flushing is not necessarily an allergy. In contrast, facial or throat swelling, difficulty breathing, or a rapidly worsening systemic reaction requires emergency evaluation. The presence of mild redness alone cannot establish the cause of a more serious symptom.
Patients should report a suspected allergy to the prescriber and pharmacist before receiving additional medication. Do not attempt to test tolerance with another tablet after a potentially serious reaction.
Commonly reported effects include headache, flushing, nasal symptoms and dyspepsia. Some patients report dizziness or nausea.
No. A headache is an adverse symptom, not evidence that a useful erectile response will occur.
Stop taking the medication and obtain urgent medical assessment.
Sudden hearing decrease or loss has been reported with PDE5 inhibitors and requires prompt medical attention.
An erection lasting longer than four hours warrants immediate emergency medical care.
Yes. QT prolongation and certain antiarrhythmic medications require explicit clinician review.
Yes. Some medications alter vardenafil exposure or blood pressure, changing the risk of symptoms.
No. Trial populations and designs differ, so rates cannot be directly compared as if they were head-to-head evidence.